Asset Details
Do you wish to reserve the book?
Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX
Do you wish to request the book?
Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX
2025
Overview
Trypanosoma vivax is a parasite that causes animal African trypanosomiasis (AAT), a chronic wasting disease that infects economically important livestock animals, which is a particular problem in African countries south of the Sahara. The impact of this disease is significant: it is responsible for over 3 million cattle deaths and an estimated $4.5 billion of annual lost productivity. There is a desperate need to develop new control measures because resistance is now widely reported to the drugs commonly used to treat this infection. We show here that a single dose of an unmodified monoclonal antibody that recognizes IFX—a parasite cell surface protein localized to the flagellum—is sufficient to cure an established T. vivax infection with no parasite reservoirs detectable in peripheral tissues. Our finding validates IFX as a new drug target and provides a rationale route to the development of new drugs to target AAT.
Publisher
American Society for Microbiology,American Society for Microbiology (ASM)
Subject
/ Animals
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - immunology
/ Antibodies, Protozoan - administration & dosage
/ Antibodies, Protozoan - immunology
/ Antigens
/ Cattle
/ Clinical Microbiology and Infectious Diseases
/ Epitopes
/ Female
/ Flagella
/ Membrane Proteins - genetics
/ Membrane Proteins - immunology
/ Mice
/ Microbial Pathogenesis and Immunology
/ Proteins
/ Protozoa
/ Protozoan Proteins - genetics
/ Protozoan Proteins - immunology
/ Transmissible spongiform encephalopathy
/ Trypanosoma vivax - drug effects
/ Trypanosoma vivax - immunology
/ Trypanosomiasis, African - drug therapy
/ Trypanosomiasis, African - parasitology
/ Vaccines
